Vicore Pharma Holding (NASDAQ:VCRE) Stock Short Interest Climbs 941.7%

Vicore Pharma Holding (NASDAQ:VCRE) was the target of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 10,709 shares, a growth of 941.7% from the October 15th total of 1,028 shares. Based on an average daily volume of 22,655 shares, the short-interest ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Chardan Capital initiated coverage on Vicore Pharma in a research report on Wednesday, November 4th. They set a “buy” rating and a $15.00 price target on the stock. Jefferies Financial Group assumed coverage on Vicore Pharma in a research note on Friday, October 9th. They set a “buy” rating and a $25.00 target price for the company. Weiss Ratings initiated coverage on Vicore Pharma in a report on Thursday, October 8th. They set a “sell (e-)” rating on the stock. Finally, Wall Street Zen upgraded Vicore Pharma to a “hold” rating in a research note on Saturday, October 24th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.00.

Vicore Pharma Stock Up 0.7%

Shares of VCRE opened at $11.35 on Wednesday. Vicore Pharma has a 52 week low of $7.88 and a 52 week high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last posted its earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $0.06 million during the quarter.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs. Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.